Top of the Month

Key to scratching cycle identified

From the News Resources of The Chronicle
Scratching an itch really does make it worse, researchers have found, and the key to the cycle is serotonin.

In a study published online in Neuron (Oct. 30, 2014), researchers from Washington University’s Center for the Study of Itch explain that it has been known for some time that scratching temporarily alleviates the sensation of itch—it co-opts the spinal nerve cells transmitting the itch signal to transmit a pain signal instead.

“The problem is that when the brain gets those pain signals, it responds by producing the neurotransmitter serotonin to help control that pain,” study author Zhou-Feng Chen, PhD, director of the Center said. “But as serotonin spreads from the brain into the spinal cord, we found the chemical can ‘jump the tracks,’ moving from pain-sensing neurons to nerve cells that influence itch intensity.”

The study used a murine mouse model engineered to lack the genes for serotonin production. When injected with a substance meant to induce itching, the mice scratched less than mice with normal serotonin production. When the mice were later injected with serotonin, scratching levels in the test mice rose to normal levels. Further testing found that serotonin in the central nervous system was activating itch-specific gastrin-releasing peptide receptor (GRPR) neurons through a parallel activation of the 5-HT1A serotonin receptor. To confirm this, some mice were injected with a compound that blocked the 5-HT1A receptor, and these mice scratched less.

“So this fits very well with the idea that itch and pain signals are transmitted through different but related pathways,” said Chen in the release.

Research

The most common reported side effects are mucocutaneous and baseline physical function were associated with poor physical function over time ............. 27

Epuris® (isotretinoin) is indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobata and recalcitrant acne in non-fasted state

Available in four strengths, taken once daily or in 100 0 6 12 18 24 30 36 42 48 54 60 66 72

Time (h)

Per protocol, the isotretinoin reference product was a generic formulation.

Other relevant warnings and precautions:

- Neurologic:
  - Migraines
  - Seizures

- Psychiatric:
  - Depression
  - Agitation
  - Suicidality

- Hematologic:
  - Thrombocytopenia

- Gastrointestinal:
  - Nausea
  - Vomiting

- Pulmonary:
  - Respiratory depression

- Other:
  - A number of cases of pseudotumor cerebri (benign intracranial hypertension), some of which involved concomitant use of isotretinoin and oral contraceptives.

- Other relevant warnings and precautions:

- Use in pregnancy:
  - Epuris® should not be prescribed if pregnancy is a risk. If pregnancy occurs during treatment, patients should be advised to use two forms of effective contraception (oral contraceptives plus a barrier method).

- Use in breastfeeding:
  - Of the patients treated with isotretinoin, 16.2% of women and 80.5% of men were breast-feeding.

- Use in children and adolescents:
  - Isotretinoin use has been associated with growth suppression in children and adolescents.

- Use in the elderly:
  - There are no adequate and well-controlled studies in the elderly. Exercise caution when prescribing this drug to elderly patients.

- Use with caution:
  - Hypertrophic scarring
  - Patients with severe recalcitrant nodular acne randomized to Epuris® or isotretinoin (0.5 mg/kg/day for the first 4 weeks; 1 mg/kg/day for the following 16 weeks).

- Use with caution in:
  - Patients who have a known metabolic or structural bone disease

Indications and clinical use:

Because of significant side effects associated with its use, Epuris® should be used with caution. Epuris® and PEER™ are trademarks of Cipher Pharmaceuticals Inc.

February 2014 - Vol. 20 No. 8

December 2014 - Vol. 20 No. 8

Published eight times per year by the proprietor, Chronicle Information Resources Ltd., with offices at 555 Bambertree Road, Ste 306, Toronto, Ont. M3C 2T5, Canada. Telephone: (416) 916-2476, Faxes: (416) 352-6199. E-mail: health@chronicle.org

Subscription rates $85.60 per year in Canada, $129.95 per year in all other countries. Single copies: $10.00 per issue (plus 17% HST).

Chronicle, The Chronicle of Skin & Allergy is a Canadian publication. The Publisher certifies that advertising placed in this publication meets Revenue Canada requirements for tax deductibility.

The Chronicle of Skin & Allergy, 555 Bambertree Road, Ste 306, Toronto, Ont. M3C 2T5. Printed in Canada.

Contacting The Chronicle

- **READER SERVICE**: To change your address, or for questions about your receipt of the journal, send an e-mail to health@chronicle.org with subject line “Circulation,” or call during business hours at 416.916.CHRON (2476), or toll-free at 866.63.CHRON (2476).

- **LETTERS**: We welcome your correspondence by mail, fax (416.352.6199), or e-mail. Kindly use the co-authors listed above.

- **ADVERTISING**: For current rates and data, please contact the publisher.

- **REPRINTS**: The content of this journal is copyrighted. Please contact Mitchell Shannon for reprint information.

The Chronicle of Skin & Allergy, 555 Bambertree Road, Ste 306, Toronto, Ont. M3C 2T5. Printed in Canada.
Therapeutic advances in rosacea, onychomycosis, psoriasis, other conditions, introduced in 2014

by LOUISE GAGNON, Correspondent, The Chronicle

Breakthroughs in small studies suggesting possible therapies for alopecia, understanding the connection between diet and acne, reports of success with biologic treatment for severe conditions like toxic epidermal necrolysis (TEN), and progress in the treatment of advanced melanoma represent some of the highlights in dermatology in 2014, according to leading Canadian dermatologists.

“The trend in treating [non-resectable] melanoma is to try to combine therapies,” says Dr. Jennifer Beecker, assistant professor, University of Ottawa, Division of Dermatology, the Ottawa Hospital. “Researchers are focusing on getting a more durable response.”

Nivolumab and pembrolizumab are some of the agents being added to the melanoma armamentarium, says Dr. Beecker, although not approved in Canada yet.

Not only are Janus kinase inhibitors like tofacitinib being used to treat psoriatic arthritis and psoriasis, but the treatment may also represent therapy for patients with alopecia in the future, says Dr. Marlene Tan Dytoc, a dermatologist in Edmonton and associate clinical professor of medicine in the Division of Dermatology and Cutaneous Sciences of the University of Alberta in Edmonton.

“Bigger controlled studies need to be done to situate it [tofacitinib] in the therapeutic ladder [to treat alopecia],” says Dr. Dytoc.

A case report of one patient found that patient experienced hair regrowth with tofacitinib, notes Dr. Dytoc. (J Invest Dermatol 2014 Jun 18).

New approach to alopecia

Still another therapy that is being studied to treat alopecia, particularly androgenetic alopecia, is platelet-rich plasma (PRP) injected in the scalp (Br J Dermatol 2013; 169(3):690-694).

“It’s another way to stimulate regrowth [of hair],” says Dr. Dytoc.

Results of a small study published this year found a significant decrease in hair loss observed between the first and fourth PRP injections (J Cutan Aesth Surg 2014 Apr; 7(2):107–111). A Vancouver-based study is being planned to look at the safety and effectiveness of PRP in androgenetic alopecia in a double-blind, randomized controlled trial.

Clinicians agree that there is raised awareness about curbing the use of antibiotics, both topical and oral, in medicine. U.S. President Barack Obama issued an executive order in Sept. 2014, aimed at combating antibiotic-resistant bacteria. The strategy called for the creation of a task force for combating antibiotic resistance, amongst other initiatives.

“There is a big shift going on with the use of antibiotics,” says Dr. Sandy Skotnicki, assistant professor, University of Toronto and medical director at Bay Dermatology Centre in Toronto. “It’s not acceptable to prescribe antibiotic monotherapy for an extended period such as six months.”

Dr. Skotnicki notes that methicillin-resistant Staph aureus is not prevalent in Europe, and postulated that its decreased prevalence there could be attributed to the use of panthenol rather than polymyxins B, bacitracin, and lidocaine therapies.

The availability of brimonidine in 2014 for rosacea patients has been of
Breakthroughs in therapy in 2014 include brimonidine

Continued from page 4

great benefit, notes Toronto dermatologist Dr. Benjamin Barankin, co-founder of the Toronto Dermatology Centre. “It’s a terrific product,” says Dr. Barankin. “It is the first-ever, true anti-redness, vasoconstrictive agent. In terms of the effect, it kicks in quickly, and it lasts the whole day. Patients occasionally experience some mild irritation, but it’s generally well-tolerated.”

New understandings of allergies

Awareness about consumer and industrial products as a source of allergy is on the radar for dermatologists. Benzophenones, ultraviolet light absorbers found in sunscreens, hair sprays, hair dyes, perfumes, shampoos, nail polish, as well as paints and varnishes, were named the 2014 Contact Allergen of the Year.

“They [benzophenones] are found in many products,” says Dr. Barankin. “It is important to bring that fact to our attention.”

Genital warts can be challenging to manage, and a new topical therapy introduced in 2014, sinecathelchins 10% ointment has been a useful addition to clinical treatment choices, notes Dr. Barankin.

“We are lacking in options for genital warts,” says Dr. Barankin. “The clearance rate is about 50 per cent, more effective in women than in men, and it’s generally well-tolerated.”

A practical tip for dermatologists who perform Mohs surgery is that they do not need to use surgical/sterile gloves to avoid the risk of infection, according to Dr. Beecker.

A study published earlier this year found no difference in the prevalence of surgical site infection with the use of sterile and non-sterile gloves for resection and reconstruction during Mohs surgery (Derm Surg 2014 Mar; 40(3):240).

“It’s significant because there is a big cost savings to the public health-care system [in using non-surgical gloves], and we are not putting our patients at risk or doing harm,” says Dr. Beecker. “The savings could be spent on something else in medicine.”

It’s a rare adverse event, but when toxic epidermal necrolysis (TEN) occurs, a potentially lethal drug reaction causing the epidermis to detach from the dermis, there are no effective therapies to treat it, and clinicians to date have turned to avenues like intravenous immunoglobulin or supportive care, but a report published this year highlighted that tumour necrosis factor alpha can be a target, according to Dr. Beecker.

“It’s a very severe reaction, and there is no gold standard for treatment,” explains Dr. Beecker. “What we are seeing that is novel is that biologics are being used to treat the severe burn-like reaction.”

A small, uncontrolled case series of patients with TEN showed that with a single subcutaneous injection of etanercept, patients responded and reached complete re-epithelialization without any side effects, with the median time to healing being 8.5 days (J Am Acad Dermatol 2014 Aug; 71(2):278-283).

“I [use of the TNF-alpha inhibitor] has not been proven, but it represents a promising concept,” notes Dr. Beecker.

The availability of adapalene 0.1%/benzoyl peroxide 2.5% topical gel in a pump dispensing system in 2014 made delivery of the product more convenient for patients with acne. In addition, a modification in the indication of the therapy, so that it can now be prescribed in children aged nine and older, widens the pool of available patients.

“Many therapies that we use for pediatric patients are off-label, so it’s nice to have an option that is on-label,” says Dr. Beecker. “We notice that some children are going through puberty earlier, and so they are getting acne earlier.”

It’s premature to offer a biologic therapy to children with atopic dermatitis, but clinicians are enthused about the prospect of having a biologic therapy in their tool kit for their adult patients in the near future.

“I think dupilumab will be a game changer for atopic dermatitis,” says Dr. Dyto. “There are many biologics for psoriasis, so it will be nice to have one for atopic dermatitis.”

Research is also looking at aprimelast, an oral phosphodiesterase 4 inhibitor recently approved in Canada for moderate to severe psoriasis, in the management of atopic dermatitis.

Another advance in 2014 was the availability of a new topical therapy, efinaconazole 10%, for onychomycosis. It can act as an alternative for patients who don’t want to take an oral therapy such as itraconazole or terbinafine or for whom oral therapies are contraindicated because of possible drug interactions.

“The mycologic cure rates are better than oral itraconazole but less than oral terbinafine,” says Dr. Dyto, noting the condition can be persistent and recurrent. “It’s more effective than ciclopirox lacquer and other topical anti-fungal solutions.”

Dr. Skotnicki says patients express a preference for using efinaconazole over ciclopirox lacquer because they can continue to apply and wear nail polish while using efinaconazole because the topical therapy can penetrate through nail polish.

“Women want to be able to cover up their nails, and that was a problem with [ciclopirox lacquer],” says Dr. Skotnicki in an interview. “The percentage of improvement is higher with [efinaconazole] than with [ciclopirox lacquer]. It’s an alternative [treatment] for people who don’t want to take oral therapies.”

Modifications to diet in acne

New pathways are suggesting that for a condition such as acne, modifications to diet can make a difference, notes Dr. Skotnicki.

A study published this year linked a typical Western diet, characterized by a high glycemic load, as possibly playing a role in acne pathogenesis (J Clin Aesthet Dermatol 2014 Jul; 7(7):46-51).

“Acne is more of a Western disease,” explains Dr. Skotnicki. “We are really starting to look at the link with diet. The answer is no longer that there is no link between diet and acne.”

Dr. Skotnicki says patients can make a choice to follow a low glycemic index to influence the pathogenesis of their acne.

Non-proprietary and brand names of therapies:

- niikumab (not available in Canada);
- pembrolizumab (not available in Canada);
- tofacitinib (Xeljanz, Pfizer Canada Inc.);
- brimonidine (Orencia, Galderma);
- secnatchins 15% (Veregen, Paladin Labs);
- etanercept (Enbrel, Amgen);
- adapalene 0.1%/benzoyl peroxide 2.5% topical gel (TactumPump, Galderma);
- dupilumab (not available in Canada); aprimelast (Otezla, Celgene Corp.);
- secnatchins 10% (Veregen, Paladin Labs); efinaconazole (Takiba, Valeant).